Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

Novo Nordisk relies on improvements in its drug delivering injection pens to maintain and gain the market share of its injectables. To that end, the company just received FDA approval for its ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity therapy CagriSema. Read mkore here.

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

The global injection pen market is projected to reach US$41.38 Billion by 2022, from US$30.97 Billion in 2017, at a CAGR of 6% during the forecast period. The market is segmented on the basis of ...

Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a ...

These days, Novo Nordisk is reincarnating many of its spent insulin pens as office furniture like chairs and lamps. It’s an increasingly common fate for the company’s used injection devices ...

Research and Markets has announced the addition of the "Global Pen Needles Market 2017-2021" report to their offering. The global pen needles market to grow at a CAGR of 10.06% during the period ...